BiovelocITA invests 680.000 euro in Amypopharma, a spin-off of the University of Milan-Bicocca
The mission of Amypopharma is the development of nanoparticles for the treatment of amyloidosis, severe diseases currently lacking effective therapies.
The mission of Amypopharma is the development of nanoparticles for the treatment of amyloidosis, severe diseases currently lacking effective therapies.